AstraZeneca wins U.S. contract to deliver 1M more doses of COVID-19 antibody therapy
Roland Magnusson/iStock Editorial via Getty Images

AstraZeneca (NASDAQ:AZN) has been awarded $855M worth of contract modification by the U.S. Department of Defense for the companyâs COVID-19 antibody therapy, AZD7442, also known as Evusheld.
According to a press release on Monday, the newly finalized deal includes 500K more doses of Evusheld the U.S. agreed to procure from AstraZeneca (AZN) in Jan. 2022. 
With an initial agreement to supply the U.S. with 700K doses of Evusheld, the total contract size now reaches 1.7M doses, the company said, adding that the government is set to roll out the additional doses at no cost.
Last December, the FDA authorized Evusheld, a combination of two long-acting antibodies called tixagevimab (AZD8895) and cilgavimab (AZD1061) for the pre-exposure prophylaxis (prevention) of COVID-19 in those aged 12 years and above.
In that age group, Evusheld is allowed for those with weaker immune systems and for individuals who cannot mount an adequate immune response to vaccines, as well as for whom vaccines are not indicated.
Welcoming the decision, Iskra Reic, Executive Vice President, Vaccines and Immune Therapies, AstraZeneca, said that the agreement was aimed at giving protection to certain segments of the U.S. society who are most vulnerable to COVID-19.
In Q4 2021, Evusheld generated $85M in revenue for the company.